Protalix BioTherapeutics, Inc.
Financial highlights
| Metric | FY 12/31/25 | FY 12/31/24 | FY 12/31/23 | FY 12/31/22 | FY 12/31/21 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $52.7 | $53.4 | $65.5 | $47.6 | $38.4 |
| Operating income | -$5.5 | $3.9 | $10.5 | -$13.0 | -$20.5 |
| Net income | -$6.6 | $2.9 | $8.3 | -$14.9 | -$27.6 |
| Cash Flow Statement | |||||
| Free cash flow | -$13.6 | $7.4 | -$2.5 | -$25.6 | -$11.7 |
Shares outstanding 80.6M · Free float 79.2%
Annual filing data through FY ended December 31, 2025; float as of September 8, 2026.